US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Biofrontera Inc Warrant

0.0501

0.0000

Volume:- -

Turnover:- -

Market Cap:534.49K

PE:-0.03

High:0.0501

Open:0.0501

Low:0.0501

Close:0.0501

52wk High:0.2770

52wk Low:0.0251

Shares:10.67M

Float Shares:10.67M

Volume Ratio:- -

T/O Rate:- -

Dividend:- -

Dividend Rate:- -

EPS(TTM):-1.8444

ROE:-325.31%

ROA:-35.18%

PB:0.03

PE(LYR):- -

Loading ...

Overview Company News Filings

Biofrontera Inc - Supplemental Nda Submission for Extremities, Neck and Trunk Indication Expected in Q3 2026

THOMSON REUTERS

Biofrontera Inc. Announces Database Lock of Phase 1 Pharmacokinetics Study of Ameluz® for Actinic Keratoses on Trunk and Extremities

THOMSON REUTERS

Biofrontera Inc - FDA Sets Pdufa Date for September 28, 2026

THOMSON REUTERS

Biofrontera Announces FDA Filing Acceptance of Supplemental New Drug Application for Ameluz® Pdt in Superficial Basal Cell Carcinoma

THOMSON REUTERS

BRIEF-Biofrontera Announces Positive Results In Phase 3 Study Of Ameluz® Pdt

Biofrontera Inc - to Submit Snda to FDA in Q3 2026

THOMSON REUTERS

Biofrontera Announces Positive Results in Phase 3 Study of Ameluz® Pdt for Actinic Keratoses on the Extremities, Neck, and Trunk, Meeting Primary Endpoint

THOMSON REUTERS

Biofrontera Inc - Ameluz Pdt Achieves 45.6% Clearance Rate in Phase 3 Study

THOMSON REUTERS

Biofrontera Inc - Primary Endpoint Achieved With Complete Clearance Rate of Ak Lesions

THOMSON REUTERS

Biofrontera Inc - Ak Lesion Clearance 73.1% in Fas and 80.3% in PPS

THOMSON REUTERS

BRIEF-Biofrontera Announces Data Base Locks For Two Clinical Studies Supporting Key Data And Regulatory Milestones

Biofrontera Inc. Announces Data Base Locks for Two Clinical Studies Supporting Key Data and Regulatory Milestones

THOMSON REUTERS

Biofrontera Inc - Plans to Submit Snda to FDA in Summer 2026

THOMSON REUTERS

Biofrontera Inc - Phase 2 Acne Study Results to FDA in Early Q3 2026

THOMSON REUTERS

BRIEF-Biofrontera Completes Transfer Of Ameluz® And Rhodoled® FDA Approval

Biofrontera Inc. Completes Transfer of Ameluz® and Rhodoled® FDA Approval and Associated Intellectual Property Portfolio

THOMSON REUTERS

BRIEF-Biofrontera announces sale of license to Xepi Antibiotic Cream to Pelthos Therapeutics for up to $10 Million

Biofrontera Inc. Announces Sale of License to Xepi® Antibiotic Cream to Pelthos Therapeutics Inc. for up to $10M

THOMSON REUTERS

Biofrontera Inc. Announces Last Patient Out in Phase 3 Study of Ameluz® (Aminolevulinic Acid Hci) Topical Gel, 10% Photodynamic Therapy (Pdt) for the Treatment of Actinic Keratoses (Ak) on the Extremities, Neck and Trunk

THOMSON REUTERS

BRIEF-Biofrontera Inc. Announces Last-Patient-Out In Phase 2B Study Of Ameluz® (Aminolevulinic Acid HCI) Topical Gel

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BFRIW/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BFRIW","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BFRIW\",,,,,undefined,":{"symbol":"BFRIW","market":"US","secType":"STK","nameCN":"Biofrontera Inc Warrant","latestPrice":0.0501,"timestamp":1771532508256,"preClose":0.0501,"halted":0,"volume":0,"delay":0,"changeRate":0,"floatShares":10668438,"shares":10668438,"eps":-1.8444,"marketStatus":"Trading","change":0,"latestTime":"02-19 15:21:48 EST","open":0.0501,"high":0.0501,"low":0.0501,"amount":0,"amplitude":0,"askPrice":0.0635,"askSize":1751,"bidPrice":0.0501,"bidSize":1100,"shortable":3,"etf":0,"ttmEps":-1.8444,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1771534800000},"marketStatusCode":2,"adr":0,"listingDate":1635480000000,"exchange":"NASDAQ","adjPreClose":0.0501,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BFRIW\",,,,,undefined,":{"symbol":"BFRIW","floatShares":10668438,"roa":"-35.18%","roe":"-325.31%","lyrEps":0,"shares":10668438,"dividePrice":0,"high":0.0501,"amplitude":0,"preClose":0.0501,"low":0.0501,"week52Low":0.0251,"pbRate":"0.03","psRate":"0.02","week52High":0.277,"institutionHeld":0,"latestPrice":0.0501,"committee":-0.228341,"eps":-1.8444,"divideRate":0,"volume":0,"delay":0,"ttmEps":-1.8444,"open":0.0501,"prevYearClose":0.09,"prevWeekClose":0.0501,"prevMonthClose":0.05,"prevQuarterClose":0.09,"fiveDayClose":0.0501,"twentyDayClose":0.052,"sixtyDayClose":0.0972},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BFRIW\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BFRIW\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BFRIW\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BFRIW\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2612507894","title":"Biofrontera Inc - Supplemental Nda Submission for Extremities, Neck and Trunk Indication Expected in Q3 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2612507894","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612507894?lang=en_us&edition=fundamental","pubTime":"2026-02-17 22:15","pubTimestamp":1771337700,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260217:nTUA2NM73Z:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BFRIW","BFRI","BK4007"],"gpt_icon":0},{"id":"2612450266","title":"Biofrontera Inc. Announces Database Lock of Phase 1 Pharmacokinetics Study of Ameluz® for Actinic Keratoses on Trunk and Extremities","url":"https://stock-news.laohu8.com/highlight/detail?id=2612450266","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612450266?lang=en_us&edition=fundamental","pubTime":"2026-02-17 22:15","pubTimestamp":1771337700,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260217:nTUA2NM73Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","BFRI","BFRIW"],"gpt_icon":0},{"id":"2610795536","title":"Biofrontera Inc - FDA Sets Pdufa Date for September 28, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2610795536","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610795536?lang=en_us&edition=fundamental","pubTime":"2026-02-11 22:15","pubTimestamp":1770819300,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260211:nTUA1M5076:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BFRIW","BK4007","BFRI"],"gpt_icon":0},{"id":"2610362955","title":"Biofrontera Announces FDA Filing Acceptance of Supplemental New Drug Application for Ameluz® Pdt in Superficial Basal Cell Carcinoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2610362955","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610362955?lang=en_us&edition=fundamental","pubTime":"2026-02-11 22:15","pubTimestamp":1770819300,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260211:nTUA1M5076:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BFRI","BFRIW","BK4007"],"gpt_icon":0},{"id":"2610065916","title":"BRIEF-Biofrontera Announces Positive Results In Phase 3 Study Of Ameluz® Pdt","url":"https://stock-news.laohu8.com/highlight/detail?id=2610065916","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610065916?lang=en_us&edition=fundamental","pubTime":"2026-02-09 22:41","pubTimestamp":1770648094,"startTime":"0","endTime":"0","summary":"BRIEF-Biofrontera Announces Positive Results In Phase 3 Study Of Ameluz Pdt Feb 9 (Reuters) - Biofrontera Inc BFRI.O:BIOFRONTERA ANNOUNCES POSITIVE RESULTS IN PHASE 3 STUDY OF AMELUZ PDT FOR ACTINIC K","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260209:nTUABHPDDP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BFRI","BFRIW","BK4007"],"gpt_icon":0},{"id":"2610971656","title":"Biofrontera Inc - to Submit Snda to FDA in Q3 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2610971656","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610971656?lang=en_us&edition=fundamental","pubTime":"2026-02-09 22:15","pubTimestamp":1770646500,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260209:nTUABHPDDP:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BFRI","BK4007","BFRIW"],"gpt_icon":0},{"id":"2610656979","title":"Biofrontera Announces Positive Results in Phase 3 Study of Ameluz® Pdt for Actinic Keratoses on the Extremities, Neck, and Trunk, Meeting Primary Endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=2610656979","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610656979?lang=en_us&edition=fundamental","pubTime":"2026-02-09 22:15","pubTimestamp":1770646500,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260209:nTUABHPDDP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BFRI","BFRIW","BK4007"],"gpt_icon":0},{"id":"2610656975","title":"Biofrontera Inc - Ameluz Pdt Achieves 45.6% Clearance Rate in Phase 3 Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2610656975","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610656975?lang=en_us&edition=fundamental","pubTime":"2026-02-09 22:15","pubTimestamp":1770646500,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260209:nTUABHPDDP:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BFRIW","BFRI","BK4007"],"gpt_icon":0},{"id":"2610569766","title":"Biofrontera Inc - Primary Endpoint Achieved With Complete Clearance Rate of Ak Lesions","url":"https://stock-news.laohu8.com/highlight/detail?id=2610569766","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610569766?lang=en_us&edition=fundamental","pubTime":"2026-02-09 22:15","pubTimestamp":1770646500,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260209:nTUABHPDDP:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","BFRIW","BFRI"],"gpt_icon":0},{"id":"2610465697","title":"Biofrontera Inc - Ak Lesion Clearance 73.1% in Fas and 80.3% in PPS","url":"https://stock-news.laohu8.com/highlight/detail?id=2610465697","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610465697?lang=en_us&edition=fundamental","pubTime":"2026-02-09 22:15","pubTimestamp":1770646500,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260209:nTUABHPDDP:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BFRIW","BK4007","BFRI"],"gpt_icon":0},{"id":"2601398253","title":"BRIEF-Biofrontera Announces Data Base Locks For Two Clinical Studies Supporting Key Data And Regulatory Milestones","url":"https://stock-news.laohu8.com/highlight/detail?id=2601398253","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601398253?lang=en_us&edition=fundamental","pubTime":"2026-01-08 22:40","pubTimestamp":1767883218,"startTime":"0","endTime":"0","summary":"BRIEF-Biofrontera Announces Data Base Locks For Two Clinical Studies Supporting Key Data And Regulatory MilestonesJan 8 (Reuters) - Biofrontera Inc BFRI.O:BIOFRONTERA INC. ANNOUNCES DATA BASE LOCKS FO","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nTUA54FNPK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BFRI","BFRIW","BK4007"],"gpt_icon":0},{"id":"2601678293","title":"Biofrontera Inc. Announces Data Base Locks for Two Clinical Studies Supporting Key Data and Regulatory Milestones","url":"https://stock-news.laohu8.com/highlight/detail?id=2601678293","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601678293?lang=en_us&edition=fundamental","pubTime":"2026-01-08 21:45","pubTimestamp":1767879900,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nTUA54FNPK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BFRI","BFRIW","BK4007"],"gpt_icon":0},{"id":"2601367825","title":"Biofrontera Inc - Plans to Submit Snda to FDA in Summer 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2601367825","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601367825?lang=en_us&edition=fundamental","pubTime":"2026-01-08 21:45","pubTimestamp":1767879900,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nTUA54FNPK:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","BFRIW","BFRI"],"gpt_icon":0},{"id":"2601336782","title":"Biofrontera Inc - Phase 2 Acne Study Results to FDA in Early Q3 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2601336782","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601336782?lang=en_us&edition=fundamental","pubTime":"2026-01-08 21:45","pubTimestamp":1767879900,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nTUA54FNPK:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","BFRI","BFRIW"],"gpt_icon":0},{"id":"2592904819","title":"BRIEF-Biofrontera Completes Transfer Of Ameluz® And Rhodoled® FDA Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2592904819","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592904819?lang=en_us&edition=fundamental","pubTime":"2025-12-18 22:14","pubTimestamp":1766067278,"startTime":"0","endTime":"0","summary":"BRIEF-Biofrontera Completes Transfer Of Ameluz And Rhodoled FDA Approval Dec 18 (Reuters) - Biofrontera Inc BFRI.O:BIOFRONTERA INC. COMPLETES TRANSFER OF AMELUZ AND RHODOLED FDA APPROVAL AND ASSOCIATE","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251218:nTUA6LBLMZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BFRIW","BFRI"],"gpt_icon":0},{"id":"2592090729","title":"Biofrontera Inc. Completes Transfer of Ameluz® and Rhodoled® FDA Approval and Associated Intellectual Property Portfolio","url":"https://stock-news.laohu8.com/highlight/detail?id=2592090729","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592090729?lang=en_us&edition=fundamental","pubTime":"2025-12-18 21:45","pubTimestamp":1766065500,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251218:nTUA6LBLMZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BFRI","BFRIW","BK4007"],"gpt_icon":0},{"id":"2581883583","title":"BRIEF-Biofrontera announces sale of license to Xepi Antibiotic Cream to Pelthos Therapeutics for up to $10 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2581883583","media":"Reuters","labels":["corporation","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581883583?lang=en_us&edition=fundamental","pubTime":"2025-11-07 21:11","pubTimestamp":1762521079,"startTime":"0","endTime":"0","summary":"BRIEF-Biofrontera announces sale of license to Xepi Antibiotic Cream to Pelthos Therapeutics for up to $10 MillionNov 7 (Reuters) - Biofrontera Inc BFRI.O:BIOFRONTERA INC. ANNOUNCES SALE OF LICENSE TO","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nTUA1LSRRQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BFRI","BFRIW"],"gpt_icon":0},{"id":"2581888468","title":"Biofrontera Inc. Announces Sale of License to Xepi® Antibiotic Cream to Pelthos Therapeutics Inc. for up to $10M","url":"https://stock-news.laohu8.com/highlight/detail?id=2581888468","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581888468?lang=en_us&edition=fundamental","pubTime":"2025-11-07 21:00","pubTimestamp":1762520402,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nTUA1LSRRQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","BFRI","BFRIW"],"gpt_icon":0},{"id":"2567486840","title":"Biofrontera Inc. Announces Last Patient Out in Phase 3 Study of Ameluz® (Aminolevulinic Acid Hci) Topical Gel, 10% Photodynamic Therapy (Pdt) for the Treatment of Actinic Keratoses (Ak) on the Extremities, Neck and Trunk","url":"https://stock-news.laohu8.com/highlight/detail?id=2567486840","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2567486840?lang=en_us&edition=fundamental","pubTime":"2025-09-16 22:30","pubTimestamp":1758033000,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250916:nTUA7R73SM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BFRI","BFRIW","BK4007"],"gpt_icon":0},{"id":"2562174241","title":"BRIEF-Biofrontera Inc. Announces Last-Patient-Out In Phase 2B Study Of Ameluz® (Aminolevulinic Acid HCI) Topical Gel","url":"https://stock-news.laohu8.com/highlight/detail?id=2562174241","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562174241?lang=en_us&edition=fundamental","pubTime":"2025-08-25 20:30","pubTimestamp":1756125029,"startTime":"0","endTime":"0","summary":"BRIEF-Biofrontera Inc. Announces Last-Patient-Out In Phase 2B Study Of Ameluz (Aminolevulinic Acid HCI) Topical GelAug 25 (Reuters) - Biofrontera Inc BFRI.O:BIOFRONTERA INC. ANNOUNCES LAST-PATIENT-OUT","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250825:nTUA69X6PP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BFRIW","BFRI"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":23,"code":"91000000","status":"200"}]}}